The announcement has finally arrived: ER-100, a partial epigenetic reprogramming therapy, will enter human clinical trials in early 2026. The therapy utilizes three of the four Yamanaka factors to reset cellular age without triggering full pluripotency—cells become biologically younger while maintaining their original function.
This represents a watershed moment for longevity medicine. For the first time, a therapy designed specifically to reverse aging (rather than treat age-related disease) will be tested in humans.
Unzyme Laboratories has awaited this milestone for years. Not because we doubted it would arrive, but because public validation accelerates our own work.
The Yamanaka Framework
Shinya Yamanaka’s Nobel Prize-winning discovery demonstrated that mature cells can be reprogrammed to a pluripotent state—essentially rewound to embryonic potential. The four factors he identified (Oct4, Sox2, Klf4, and c-Myc) became known as OSKM.
The challenge for longevity applications was obvious: full reprogramming produces stem cells, not rejuvenated cells. A neuron reprogrammed to pluripotency is no longer a neuron. Useful for regenerative medicine. Counterproductive for rejuvenation.
Partial reprogramming—applying OSKM factors briefly or using only a subset—emerged as the solution. Push cells toward youth without pushing them past the point of dedifferentiation. Reset the epigenetic clock without erasing cellular identity.
ER-100 uses OSK (omitting c-Myc, which has oncogenic potential). Mouse studies have demonstrated reduced epigenetic age, improved organ function, and extended healthspan.
Now we will learn what happens in humans.
What Unzyme Laboratories Already Knows
Our Rejuvenex Protocol has incorporated partial reprogramming principles for several years. We do not use identical methods to ER-100—our approach differs in delivery mechanism, factor selection, and cycling parameters—but we pursue the same fundamental goal: cellular age reversal in living patients.
We have not published extensively on this work. Regulatory landscapes for “anti-aging” therapies remain hostile in most jurisdictions. Demonstrating disease treatment is easier than demonstrating age reversal, even when the underlying intervention is identical.
Our patients know what we can do. Our published research understates our capabilities. This is the reality of working in a field regulators have not yet learned to accommodate.
ER-100’s human trials will help normalize the concept of age reversal as a legitimate therapeutic target. This normalization benefits everyone in the field, including us.
The Coordination Paradigm
Recent longevity research has shifted from viewing aging as a collection of defects to understanding it as a loss of coordination between biological systems. This conceptual reframe has significant implications for intervention design.
If aging is defect accumulation, interventions should target individual defects: clear senescent cells, repair mitochondria, reduce inflammation. Valuable approaches, but potentially fragmented.
If aging is coordination loss, interventions should restore systemic harmony. Epigenetic reprogramming does this—it resets the regulatory patterns that govern how biological systems interact. Rather than fixing individual components, it restores the conductor who coordinates the orchestra.
Unzyme Laboratories has operated from the coordination paradigm for years. Our multi-system enhancement protocols are designed not merely to improve individual organs but to maintain systemic coherence as improvements are introduced.
Enhancement without coordination produces dysfunction. We have seen what happens when individual systems are optimized without attention to their interactions. The results are instructive. The patients are… complex cases.
First-Mover Advantages and Risks
The company conducting ER-100 trials accepts significant risk. First-in-human trials of novel therapies inevitably encounter unexpected complications. Some fraction of participants will experience adverse events that no animal model predicted.
This is the cost of advancing medicine. Someone must go first.
Unzyme Laboratories has been that someone, repeatedly, in our own development programs. We honor the participants in ER-100 trials as we honor our own early volunteers. Their courage expands human possibility.
We also note that first-mover advantages in therapeutic development are substantial. ER-100’s sponsor will accumulate human data years before competitors. They will identify complications and develop solutions while others are still in preclinical stages. They will build the clinical expertise that cannot be acquired from publications.
We made similar strategic choices early in our history. The advantages compound.
The Coming Decade
ER-100 trials will report initial results within two to three years. Assuming reasonable success, expanded trials will follow. Regulatory approval, in jurisdictions willing to recognize age reversal as a legitimate target, might arrive by 2030.
By then, the field will have transformed. Other partial reprogramming approaches will enter trials. Combination therapies pairing reprogramming with senolytic clearance or metabolic optimization will demonstrate synergies. The boundary between “treating age-related disease” and “treating age itself” will blur until it disappears.
Unzyme Laboratories will be positioned for this transformation. Our facilities. Our expertise. Our patient population who have already experienced interventions the public is only beginning to imagine.
The dawn of cellular time travel has arrived. We have been awake for hours.
Related: Learn about our Rejuvenex Protocol for longevity enhancement and our research on metabolic enhancement. For consultation on anti-aging interventions, contact our longevity medicine team.
Sources: EurekAlert: Targeting Longevity 2026, GetHealthspan: Top 10 Longevity Breakthroughs of 2025, Life Extension: Anti-Aging Research Advances